Gyre Therapeutics (GYRE) Invested Capital (2010 - 2018)

Gyre Therapeutics (GYRE) has reported Invested Capital for 5 consecutive years, with $478000.0 the latest figure, recorded in Q3 2014.

• In Q3 2014, Invested Capital fell 45.25% year-over-year to $478000.0; the TTM figure through Jun 2015 stood at $478000.0 (down 85.07% YoY), while the FY2013 annual figure was $853000.0, changed 0.24% from the prior year.
• Invested Capital eased to $478000.0 in Q3 2014 per GYRE's latest filing, from $699000.0 in the prior quarter.
• Across five years, Invested Capital topped out at $1.9 million in Q2 2011 and bottomed at $478000.0 in Q3 2014.
• Historically, Invested Capital has averaged $1.0 million across 5 years, with a median of $866000.0 in 2013.
• Annual changes were most pronounced in 2012 — Invested Capital tumbled 54.5% — and 2013, when it climbed 3.44%.
• Gyre Therapeutics' Invested Capital stood at $1.7 million in 2010, then declined by 27.43% to $1.2 million in 2011, then sank by 31.43% to $851000.0 in 2012, then gained by 0.24% to $853000.0 in 2013, then tumbled by 43.96% to $478000.0 in 2014.
• Business Quant data shows GYRE's Invested Capital at $478000.0 in Q3 2014, $699000.0 in Q2 2014, and $776000.0 in Q1 2014.